Collaborative arrangement milestone payments.

No definition available.

Name:	janx_CollaborativeArrangementMilestonePayments
Namespace Prefix:	janx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Developmental milestone.

+ References

No definition available.

+ Details

Name:	janx_DevelopmentalMilestone
Namespace Prefix:	janx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone payments per collaboration target.

+ References

No definition available.

+ Details

Name:	janx_MilestonePaymentsPerCollaborationTarget
Namespace Prefix:	janx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone payments upon successful completion of certain commercial milestones.

+ References

No definition available.

+ Details

Name:	janx_MilestonePaymentsUponSuccessfulCompletionOfCertainCommercialMilestones
Namespace Prefix:	janx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Non-refundable and non-creditable upfront fee.

+ References

No definition available.

+ Details

Name:	janx_NonRefundableAndNonCreditableUpfrontFee
Namespace Prefix:	janx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of Collaborative Arrangement Targets

+ References

No definition available.

+ Details

Name:	janx_NumberOfCollaborativeArrangementTargets
Namespace Prefix:	janx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Payable upon selection of second collaboration target.

+ References

No definition available.

+ Details

Name:	janx_PayableUponSelectionOfSecondCollaborationTarget
Namespace Prefix:	janx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Remaining term of research services revenue recognized.

+ References

No definition available.

+ Details

Name:	janx_RemainingTermOfResearchServicesRevenueRecognized
Namespace Prefix:	janx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Definition

Transaction price agreement initial determined amount.

+ References

No definition available.

+ Details

Name:	janx_TransactionPriceAgreementInitialDeterminedAmount
Namespace Prefix:	janx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Transaction price allocated for performance obligations.

+ References

No definition available.

+ Details

Name:	janx_TransactionPriceAllocatedForPerformanceObligations
Namespace Prefix:	janx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Upfront payment received.

+ References

No definition available.

+ Details

Name:	janx_UpfrontPaymentReceived
Namespace Prefix:	janx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_DeferredRevenueCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

+ Details

Name:	us-gaap_ReceivablesNetCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483041/730-20-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483041/730-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=janx_MerckAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=janx_BMSAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration Revenue - Additional Information (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($) Target	Jun. 30, 2025 USD ($)	Dec. 31, 2025 USD ($)
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research and development expense	$ 30,994,000	$ 34,664,000	$ 57,807,000	$ 59,719,000
Accounts receivable outstanding	149,000		$ 149,000		$ 0
Merck Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Number of collaboration targets \| Target			2
Non-refundable and non-creditable upfront fee			$ 8,000,000
Payable upon selection of second collaboration target	8,000,000		8,000,000
Milestone payments			285,000,000
Revenue recognized	0	$ 0	0	$ 0
Merck Agreement \| Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments per collaboration target			142,500,000
Milestone payments upon successful completion of certain commercial milestones			350,000,000
BMS Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Non-refundable and non-creditable upfront fee			15,000,000
Upfront payment received			15,000,000
Developmental milestone			35,000,000
Revenue recognized	10,300,000		14,000,000
Transaction price agreement initial determined amount			56,700,000
Research and development expense			6,700,000
Transaction price allocated for performance obligations			42,700,000
Deferred revenue	36,100,000		36,100,000
Deferred revenue current	35,100,000		35,100,000
Accounts receivable outstanding	$ 100,000		$ 100,000
Remaining term of research services revenue recognized	1 year 3 months 18 days		1 year 3 months 18 days
BMS Agreement \| Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments upon successful completion of certain commercial milestones			$ 750,000,000